DK2968493T3 - Forbedrede poxvirusvacciner. - Google Patents

Forbedrede poxvirusvacciner. Download PDF

Info

Publication number
DK2968493T3
DK2968493T3 DK14723475.1T DK14723475T DK2968493T3 DK 2968493 T3 DK2968493 T3 DK 2968493T3 DK 14723475 T DK14723475 T DK 14723475T DK 2968493 T3 DK2968493 T3 DK 2968493T3
Authority
DK
Denmark
Prior art keywords
leu
seq
ser
ala
pro
Prior art date
Application number
DK14723475.1T
Other languages
English (en)
Inventor
Riccardo Cortese
Stefano Colloca
Antonella Folgori
Alfredo Nicosia
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Application granted granted Critical
Publication of DK2968493T3 publication Critical patent/DK2968493T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (17)

1. Vektor med modificeret vaccinia-virus af Ankara-stammen (MVA), omfattende et nukleinsyrekonstrukt, hvilket nukleinsyrekonstrukt omfatter: (i) en nukleinsyre kodende for mindst ét antigent protein eller antigent fragment deraf, virkningsmæssigt forbundet til (ii) en nukleinsyre kodende for mindst én invariant kæde; hvor den mindst ene invariante kæde har mindst 85 % sekvenssimilaritet med den humane isoform p35 i SEQ ID NO:1, p43 i SEQ ID NO:5 eller c i SEQ ID NO:9 eller en af muse-isoformerne p31 i SEQ ID NO:3 eller p41 i SEQ ID NO:7.
2. MVA-vektor ifølge krav 1, hvor den mindst ene kodede invariante kæde er af pattedyroprindelse.
3. MVA-vektor ifølge enten krav 1 eller 2, hvor den kodede mindst ene invariante kæde er human isoform p35 i SEQ ID NO:1, p43 i SEQ ID NO:5 eller c i SEQ ID NO:9 eller en af museisoformerne p31 i SEQ ID NO:3 eller p41 i SEQ ID NO:7.
4. MVA-vektor ifølge enten krav 1 eller 2, hvor den kodede mindst ene invariante kæde har mindst 90 % sekvenssimilaritet med SEQ ID NO:1 eller SEQ ID NO:3.
5. MVA-vektor ifølge krav 4, hvor den kodede mindst ene invariante kæde har mindst 99 % sekvenssimilaritet med SEQ ID NO:1 eller SEQ ID NO:3.
6. MVA-vektor ifølge et hvilket som helst af kravene 1 til 5, hvor det mindst ene antigene protein er et protein fra en virus, en bakterie, en protist eller en flercellet parasit.
7. MVA-vektor ifølge et hvilket som helst af kravene 1 til 6 til anvendelse i forberedelse eller forstærkning af en immunreaktion.
8. MVA-vektor til anvendelse ifølge krav 7, hvor forberedelsen af immunreaktionen er del af et homologt forberedelses-forstærknings-vaccinationsprogram.
9. MVA-vektor til anvendelse ifølge krav 7, hvor forberedelsen af immunreaktionen er del af et heterologt forberedelses-forstærknings-vaccinationsprogram.
10. Vaccinekombination omfattende: (a) en MVA-vektor omfattende et nukleinsyrekonstrukt, hvor nukleinsyrekonstruktet omfatter: (i) en nukleinsyresekvens kodende for mindst et første antigent protein eller antigent fragment deraf, virkningsmæssigt forbundet til (ii) en nukleinsyre kodende for mindst én invariant kæde, hvor den mindst ene invariante kæde har mindst 85 % sekvenssimilaritet med human isoform p35 i SEQ ID NO:1, p43 i SEQ ID NO:5 eller c i SEQ ID NO:9 eller en af museisoformerne p31 i SEQ ID NO:3 eller p41 i SEQ ID NO:7 og (b) en adenovirusvektor omfattende en nukleinsyresekvens kodende for mindst et andet antigent protein eller antigent fragment deraf, hvor mindst én epitop af det første antigene protein eller antigene fragment deraf genkendes af det samme antistof, T-celle eller B-celle til det andet antigene protein eller fragment deraf.
11. Vaccinekombination ifølge krav 10, hvor den invariante kæde er human isoform p35 i SEQ ID NO:1, p43 i SEQ ID NO:5 eller c i SEQ ID NO:9 eller en af museisoformerne p31 i SEQ ID NO:3 eller p41 i SEQ ID NO:7.
12. Vaccinekombination ifølge krav 10, hvor den invariante kæde har mindst 90 % sekvenssimilaritet med SEQ ID NO:1 eller SEQ ID NO:3.
13. Vaccinekombination ifølge krav 12, hvor den invariante kæde har mindst 99 % sekvenssimilaritet med SEQ ID NO:1 eller SEQ ID NO:3.
14. Vaccinekombination ifølge et hvilket som helst af kravene 10 til 13, hvor adenovirusvektoren er en ikke-human menneskeabe-afledt adenovirusvektor, fortrinsvis en chimpanse- eller bonobo-adenovirusvektor.
15. Vaccinekombination ifølge et hvilket som helst af kravene 10 til 14 til anvendelse i et forberedelses-forstærknings-vaccinationsprogram.
16. MVA-vektor ifølge krav 1 til anvendelse som lægemiddel.
17. MVA-vektor ifølge krav 1 til anvendelse i stimulering af en immunreaktion hos et individ.
DK14723475.1T 2013-03-15 2014-03-14 Forbedrede poxvirusvacciner. DK2968493T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2013/055409 WO2014139587A1 (en) 2013-03-15 2013-03-15 Improved poxviral vaccines
PCT/IB2014/059802 WO2014141176A1 (en) 2013-03-15 2014-03-14 Improved poxviral vaccines

Publications (1)

Publication Number Publication Date
DK2968493T3 true DK2968493T3 (da) 2018-09-17

Family

ID=47882194

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14723475.1T DK2968493T3 (da) 2013-03-15 2014-03-14 Forbedrede poxvirusvacciner.

Country Status (17)

Country Link
US (3) US20160000904A1 (da)
EP (1) EP2968493B1 (da)
JP (1) JP6702725B2 (da)
CN (2) CN109182378A (da)
BE (1) BE1021192B1 (da)
BR (1) BR112015023524B1 (da)
CA (1) CA2907026A1 (da)
CY (1) CY1120740T1 (da)
DK (1) DK2968493T3 (da)
ES (1) ES2685922T3 (da)
HR (1) HRP20181376T1 (da)
HU (1) HUE040189T2 (da)
LT (1) LT2968493T (da)
PL (1) PL2968493T3 (da)
PT (1) PT2968493T (da)
SI (1) SI2968493T1 (da)
WO (2) WO2014139587A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576143B2 (en) 2013-03-15 2020-03-03 Glaxosmithkline Biologicals Sa Poxviral vaccines
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
WO2017025782A1 (en) * 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
JP6893177B2 (ja) 2015-05-15 2021-06-23 キュアバック アーゲー 少なくとも１つのｍＲＮＡコンストラクトの投与を含むプライムブーストレジメン（ＰＲＩＭＥ−ＢＯＯＳＴ ＲＥＧＩＭＥＮＳ）
MX2019002178A (es) 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
EP3651798A1 (en) * 2017-07-12 2020-05-20 Nouscom AG Neoantigen vaccine composition for treatment of cancer
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201812647D0 (en) * 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
WO2020128012A1 (en) * 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
CA3132601A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
CN111057716B (zh) * 2019-07-27 2022-04-15 中国人民解放军军事科学院军事医学研究院 用于包装重组人4型腺病毒的单质粒载体系统及其应用
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
JP4475561B2 (ja) 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスワクチン
IL164177A0 (en) * 2002-05-16 2005-12-18 Bavarian Nordic As Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
EP1711518B1 (en) 2004-01-23 2009-11-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Chimpanzee adenovirus vaccine carriers
PL1957528T3 (pl) 2005-11-30 2013-03-29 Univ Copenhagen Szczepionka nukleotydowa
RU2011125306A (ru) * 2008-11-21 2012-12-27 Юнивёрсити Оф Копенгаген Праймирование иммунного ответа
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
US10576143B2 (en) * 2013-03-15 2020-03-03 Glaxosmithkline Biologicals Sa Poxviral vaccines
GB201321384D0 (en) 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
MX2019002178A (es) 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).

Also Published As

Publication number Publication date
CN105307674A (zh) 2016-02-03
EP2968493B1 (en) 2018-06-13
US11278614B2 (en) 2022-03-22
WO2014139587A1 (en) 2014-09-18
BR112015023524B1 (pt) 2023-10-31
US20200164061A1 (en) 2020-05-28
US20160000904A1 (en) 2016-01-07
JP2016510989A (ja) 2016-04-14
BE1021192B1 (fr) 2016-10-21
US20180125968A1 (en) 2018-05-10
PT2968493T (pt) 2018-10-03
JP6702725B2 (ja) 2020-06-03
CN109182378A (zh) 2019-01-11
SI2968493T1 (sl) 2018-12-31
PL2968493T3 (pl) 2018-11-30
CY1120740T1 (el) 2019-12-11
ES2685922T3 (es) 2018-10-15
US10588961B2 (en) 2020-03-17
WO2014141176A1 (en) 2014-09-18
LT2968493T (lt) 2018-09-10
HRP20181376T1 (hr) 2018-10-19
BR112015023524A2 (pt) 2017-10-24
EP2968493A1 (en) 2016-01-20
CA2907026A1 (en) 2014-09-18
HUE040189T2 (hu) 2019-02-28

Similar Documents

Publication Publication Date Title
US11278614B2 (en) Poxviral vaccines
US20190175720A1 (en) Zika virus vaccine and combination vaccine
EA038250B1 (ru) Рекомбинантный белок gl цитомегаловируса с мутацией в сайте распознавания протеазой, которая уменьшает протеазное расщепление
JP7544399B2 (ja) Ｃｏｖｉｄ－１９に対する保護のための弱毒化されたポックスウイルスベクターをベースとするワクチン
US20110129498A1 (en) Vaccine for the prevention and therapy of hcv infections
EP2959915A1 (en) A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
AU2012275319A1 (en) Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of Dengue virus infection
US10576143B2 (en) Poxviral vaccines
WO2017025782A1 (en) Improved poxviral vaccines
US9284356B2 (en) Identification of a west nile virus CD4 T cell epitope and use thereof
KR20200100686A (ko) B형 간염 면역화 레지멘 및 조성물
WO2023081936A2 (en) Sars-cov-2 vaccines
Elahi et al. Investigation of the immunological properties of the bovine viral diarrhea virus protein NS3 expressed by an adenovirus vector in mice
JP2023528984A (ja) コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン
JP7240029B2 (ja) フラビウイルスとリッサウイルスとのキメラワクチン
Kuhs Development of novel Hepatitis C Virus DNA vaccines